Todd Brady, Aldeyra Therapeutics CEO
Aldeyra touts first part of PhIII for rare eye disease but questions remain as FDA meeting approaches
An 18-year-old biotech is growing up with some positive data out of the first part of a Phase III study in a rare eye disease …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
